Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 2
2005 2
2006 2
2007 8
2008 10
2009 5
2010 4
2011 9
2012 15
2013 14
2014 17
2015 16
2016 24
2017 12
2018 20
2019 18
2020 18
2021 16
2022 26
2023 33
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

239 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Schlumberger M, et al. Among authors: krzyzanowska mk. N Engl J Med. 2015 Feb 12;372(7):621-30. doi: 10.1056/NEJMoa1406470. N Engl J Med. 2015. PMID: 25671254 Free article. Clinical Trial.
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Führer D, Keam B, Bardet S, Sherman EJ, Tahara M, Hu MI, Singh R, Lin Y, Soldatenkova V, Wright J, Lin B, Maeda P, Capdevila J, Wirth LJ; LIBRETTO-531 Trial Investigators. Hadoux J, et al. N Engl J Med. 2023 Nov 16;389(20):1851-1861. doi: 10.1056/NEJMoa2309719. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870969 Clinical Trial.
A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer.
Brose MS, Panaseykin Y, Konda B, de la Fouchardiere C, Hughes BGM, Gianoukakis AG, Joo Park Y, Romanov I, Krzyzanowska MK, Leboulleux S, Binder TA, Dutcus C, Xie R, Taylor MH. Brose MS, et al. Among authors: krzyzanowska mk. J Clin Endocrinol Metab. 2022 Feb 17;107(3):776-787. doi: 10.1210/clinem/dgab731. J Clin Endocrinol Metab. 2022. PMID: 34664662 Free PMC article. Clinical Trial.
Drug interactions and oncological outcomes: a hidden adversary.
Riechelmann RP, Krzyzanowska MK. Riechelmann RP, et al. Among authors: krzyzanowska mk. Ecancermedicalscience. 2019 Mar 28;13:ed88. doi: 10.3332/ecancer.2019.ed88. eCollection 2019. Ecancermedicalscience. 2019. PMID: 31123502 Free PMC article.
Transitioning to a New Normal in the Post-COVID Era.
Jiang DM, Berlin A, Moody L, Kumar R, Hannon B, Krzyzanowska MK, Dhani N, Cole H, Elliott M, Sridhar SS. Jiang DM, et al. Among authors: krzyzanowska mk. Curr Oncol Rep. 2020 Jun 22;22(7):73. doi: 10.1007/s11912-020-00956-1. Curr Oncol Rep. 2020. PMID: 32566960 Free PMC article. Review. No abstract available.
Reply to F. Poizeau et al.
Eng L, Sutradhar R, Krzyzanowska MK. Eng L, et al. Among authors: krzyzanowska mk. J Clin Oncol. 2023 Nov 10;41(32):5073-5075. doi: 10.1200/JCO.23.01191. Epub 2023 Aug 23. J Clin Oncol. 2023. PMID: 37611213 No abstract available.
239 results